Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-06-2015 | Review – Cancer Research

Klotho: a novel biomarker for cancer

Authors: Xiangxiang Zhou, Xin Wang

Published in: Journal of Cancer Research and Clinical Oncology | Issue 6/2015

Abstract

Background

The Klotho gene was originally identified as an anti-aging gene in 1997. Recent studies have demonstrated aberrant expression of Klotho in a number of cancers, including breast cancer, lung cancer, hepatocellular carcinoma (HCC), and so on.

Methods

A literature search focusing on dysregulation of Klotho and its possible mechanisms in cancer was performed.

Results and conclusions

Downregulation of Klotho was found in several cancers, such as pancreatic cancer, HCC, and other tumors. Epigenetic modulation, such as promoter methylation and histone deacetylation, also contributed to the dysregulation of Klotho in cancers. Downregulation of Klotho resulted in promoted proliferation and reduced apoptosis of cancer cells. The relevant mechanisms include the fibroblast growth factor signaling, the insulin-like growth factor 1 receptor pathway, and the Wnt/β-catenin signaling pathway. Furthermore, the Klotho protein hopefully provides new insights into cancer target treatment.

Abraham CR, Chen C, Cuny GD, Glicksman MA, Zeldich E (2012) Small-molecule Klotho enhancers as novel treatment of neurodegeneration. Future Med Chem 4:1671–1679. doi:10.4155/fmc.12.134 CrossRefPubMedCentralPubMed

Abramovitz L et al (2011) KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in pancreatic cancer. Clin Cancer Res 17:4254–4266. doi:10.1158/1078-0432.CCR-10-2749 CrossRefPubMed

Alvarez AA, Krigman HR, Whitaker RS, Dodge RK, Rodriguez GC (1999) The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 5:587–591PubMed

Arking DE et al (2002) Association of human aging with a functional variant of klotho. Proc Natl Acad Sci USA 99:856–861. doi:10.1073/pnas.022484299 CrossRefPubMedCentralPubMed

Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M (2012) Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 11:384–400. doi:10.1038/nrd3674 CrossRefPubMed

Bartels CL, Tsongalis GJ (2009) MicroRNAs: novel biomarkers for human cancer. Clin Chem 55:623–631. doi:10.1373/clinchem.2008.112805 CrossRefPubMed

Berhoune M, Banu E, Scotte F, Prognon P, Oudard S, Bonan B (2008) Therapeutic strategy for treatment of metastatic non-small cell lung cancer. Ann Pharmacother 42:1640–1652. doi:10.1345/aph.1L200 CrossRefPubMed

Brooks AN, Kilgour E, Smith PD (2012) Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 18:1855–1862. doi:10.1158/1078-0432.CCR-11-0699 CrossRefPubMed

Camilli TC et al (2011) Loss of Klotho during melanoma progression leads to increased filamin cleavage, increased Wnt5A expression, and enhanced melanoma cell motility. Pigment Cell Melanoma Res 24:175–186. doi:10.1111/j.1755-148X.2010.00792.x CrossRefPubMedCentralPubMed

Chang B et al (2012) Klotho inhibits the capacity of cell migration and invasion in cervical cancer. Oncol Rep 28:1022–1028. doi:10.3892/or.2012.1865 PubMed

Chen B, Wang X, Zhao W, Wu J (2010) Klotho inhibits growth and promotes apoptosis in human lung cancer cell line A549. J Exp Clin Cancer Res 29:99. doi:10.1186/1756-9966-29-99 CrossRefPubMedCentralPubMed

Chen B, Ma X, Liu S, Zhao W, Wu J (2012) Inhibition of lung cancer cells growth, motility and induction of apoptosis by Klotho, a novel secreted Wnt antagonist, in a dose-dependent manner. Cancer Biol Ther 13:1221–1228. doi:10.4161/cbt.21420 CrossRefPubMedCentralPubMed

Chen J, Zhang X, Zhang H, Lin J, Zhang C, Wu Q, Ding X (2013a) Elevated Klotho promoter methylation is associated with severity of chronic kidney disease. PLoS One 8:e79856. doi:10.1371/journal.pone.0079856 CrossRefPubMedCentralPubMed

Chen L et al (2013b) Klotho endows hepatoma cells with resistance to anoikis via VEGFR2/PAK1 activation in hepatocellular carcinoma. PLoS One 8:e58413. doi:10.1371/journal.pone.0058413 CrossRefPubMedCentralPubMed

Doi S et al (2011) Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 286:8655–8665. doi:10.1074/jbc.M110.174037 CrossRefPubMedCentralPubMed

Drueke TB, Massy ZA (2013) Circulating Klotho levels: clinical relevance and relationship with tissue Klotho expression. Kidney Int 83:13–15. doi:10.1038/ki.2012.370 CrossRefPubMed

Feng S, Dakhova O, Creighton CJ, Ittmann M (2013) Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res 73:2551–2562. doi:10.1158/0008-5472.CAN-12-4108 CrossRefPubMedCentralPubMed

Fu T, Choi SE, Kim DH, Seok S, Suino-Powell KM, Xu HE, Kemper JK (2012) Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor beta-Klotho. Proc Natl Acad Sci USA 109:16137–16142. doi:10.1073/pnas.1205951109 CrossRefPubMedCentralPubMed

Fukino K, Suzuki T, Saito Y, Shindo T, Amaki T, Kurabayashi M, Nagai R (2002) Regulation of angiogenesis by the aging suppressor gene klotho. Biochem Biophys Res Commun 293:332–337. doi:10.1016/S0006-291X(02)00216-4 CrossRefPubMed

Gallagher EJ, LeRoith D (2010) The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 21:610–618. doi:10.1016/j.tem.2010.06.007 CrossRefPubMedCentralPubMed

Gan LH, Pan J, Chen SJ, Zhong J, Wang LJ (2011) DNA methylation of ZIC1 and KLOTHO gene promoters in colorectal carcinomas and its clinicopathological significance. Zhejiang Da Xue Xue Bao Yi Xue Ban 40:309–314PubMed

Ge X, Wang X (2010) Role of Wnt canonical pathway in hematological malignancies. J Hematol Oncol 3:33. doi:10.1186/1756-8722-3-33 CrossRefPubMedCentralPubMed

Greulich H, Pollock PM (2011) Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med 17:283–292. doi:10.1016/j.molmed.2011.01.012 CrossRefPubMed

Hu MC, Moe OW (2012) Klotho as a potential biomarker and therapy for acute kidney injury. Nat Rev Nephrol 8:423–429. doi:10.1038/nrneph.2012.92 CrossRefPubMedCentralPubMed

Hu MC, Shi M, Zhang J, Quinones H, Kuro-o M, Moe OW (2010) Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney Int 78:1240–1251. doi:10.1038/ki.2010.328 CrossRefPubMedCentralPubMed

Huang YT et al (2013) PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy. J Transl Med 11:245. doi:10.1186/1479-5876-11-245 CrossRefPubMedCentralPubMed

Hudelist G et al (2007) Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations. Endocr Relat Cancer 14:1053–1062. doi:10.1677/ERC-06-0075 CrossRefPubMed

Ito S, Kinoshita S, Shiraishi N, Nakagawa S, Sekine S, Fujimori T, Nabeshima YI (2000) Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech Dev 98:115–119CrossRefPubMed

Iyoda A, Hiroshima K, Toyozaki T, Haga Y, Fujisawa T, Ohwada H (2001) Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer 91:1992–2000CrossRefPubMed

Jacot W et al (2013) BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer. BMC Cancer 13:523. doi:10.1186/1471-2407-13-523 CrossRefPubMedCentralPubMed

Joeckel TE, Lubbert M (2012) Clinical results with the DNA hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update. Semin Hematol 49:330–341. doi:10.1053/j.seminhematol.2012.08.001 CrossRefPubMed

Kharitonenkov A (2009) FGFs and metabolism. Curr Opin Pharmacol 9:805–810. doi:10.1016/j.coph.2009.07.001 CrossRefPubMed

King GD et al (2012) Identification of novel small molecules that elevate Klotho expression. Biochem J 441:453–461. doi:10.1042/BJ20101909 CrossRefPubMedCentralPubMed

Kitagawa M et al (2013) A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. PLoS One 8:e56695. doi:10.1371/journal.pone.0056695 CrossRefPubMedCentralPubMed

Klaus A, Birchmeier W (2008) Wnt signalling and its impact on development and cancer. Nat Rev Cancer 8:387–398. doi:10.1038/nrc2389 CrossRefPubMed

Kuro-o M (2009) Klotho and aging. Biochim Biophys Acta 1790:1049–1058. doi:10.1016/j.bbagen.2009.02.005 CrossRefPubMedCentralPubMed

Kuro-o M (2010) Klotho. Pflugers Arch 459:333–343. doi:10.1007/s00424-009-0722-7 CrossRefPubMed

Kuro-o M et al (1997) Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45–51. doi:10.1038/36285 CrossRefPubMed

Kurosu H et al (2005) Suppression of aging in mice by the hormone Klotho. Science 309:1829–1833. doi:10.1126/science.1112766 CrossRefPubMedCentralPubMed

Lee J et al (2010) The anti-aging gene KLOTHO is a novel target for epigenetic silencing in human cervical carcinoma. Mol Cancer 9:109. doi:10.1186/1476-4598-9-109 CrossRefPubMedCentralPubMed

Lim SC, Liu JJ, Subramaniam T, Sum CF (2013) Elevated circulating alpha-klotho by angiotensin II receptor blocker losartan is associated with reduction of albuminuria in type 2 diabetic patients. J Renin Angiotensin Aldosterone Syst. doi:10.1177/1470320313475905 PubMed

Lin BC, Wang M, Blackmore C, Desnoyers LR (2007) Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 282:27277–27284. doi:10.1074/jbc.M704244200 CrossRefPubMed

Liu H et al (2007) Augmented Wnt signaling in a mammalian model of accelerated aging. Science 317:803–806. doi:10.1126/science.1143578 CrossRefPubMed

Lu L, Katsaros D, Wiley A, de la Longrais IA, Puopolo M, Yu H (2008) Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression. Cancer Invest 26:185–192. doi:10.1080/07357900701638343 CrossRefPubMed

Maor S, Yosepovich A, Papa MZ, Yarden RI, Mayer D, Friedman E, Werner H (2007) Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations. Cancer Lett 257:236–243. doi:10.1016/j.canlet.2007.07.019 CrossRefPubMed

Mian IS (1998) Sequence, structural, functional, and phylogenetic analyses of three glycosidase families. Blood Cells Mol Dis 24:83–100. doi:10.1006/bcmd.1998.9998 PubMed

Nagasu H et al (2011) Overexpression of klotho protein modulates uninephrectomy-induced compensatory renal hypertrophy by suppressing IGF-I signals. Biochem Biophys Res Commun 407:39–43. doi:10.1016/j.bbrc.2011.02.089 CrossRefPubMed

Ogawa Y et al (2007) BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci USA 104:7432–7437. doi:10.1073/pnas.0701600104 CrossRefPubMedCentralPubMed

Poh W, Wong W, Ong H, Aung MO, Lim SG, Chua BT, Ho HK (2012) Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. Mol Cancer 11:14. doi:10.1186/1476-4598-11-14 CrossRefPubMedCentralPubMed

Polakis P (2000) Wnt signaling and cancer. Genes Dev 14:1837–1851PubMed

Razzaque MS (2010) Therapeutic potential of klotho-FGF23 fusion polypeptides: WO2009095372. Expert Opin Ther Pat 20:981–985. doi:10.1517/13543771003774100 CrossRefPubMedCentralPubMed

Rosenzweig SA, Atreya HS (2010) Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol 80:1115–1124. doi:10.1016/j.bcp.2010.06.013 CrossRefPubMedCentralPubMed

Rubinek T et al (2012) Epigenetic silencing of the tumor suppressor klotho in human breast cancer. Breast Cancer Res Treat 133:649–657. doi:10.1007/s10549-011-1824-4 CrossRefPubMed

Scheller M, Huelsken J, Rosenbauer F, Taketo MM, Birchmeier W, Tenen DG, Leutz A (2006) Hematopoietic stem cell and multilineage defects generated by constitutive beta-catenin activation. Nat Immunol 7:1037–1047. doi:10.1038/ni1387 CrossRefPubMed

Shimada T et al (2004) Angiogenesis and vasculogenesis are impaired in the precocious-aging klotho mouse. Circulation 110:1148–1155. doi:10.1161/01.CIR.0000139854.74847.99 CrossRefPubMed

Shu G et al (2013) Restoration of klotho expression induces apoptosis and autophagy in hepatocellular carcinoma cells. Cell Oncol (Dordr) 36:121–129. doi:10.1007/s13402-012-0118-0 CrossRef

Tohyama O, Imura A, Iwano A, Freund JN, Henrissat B, Fujimori T, Nabeshima Y (2004) Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronides. J Biol Chem 279:9777–9784. doi:10.1074/jbc.M312392200 CrossRefPubMed

Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10:116–129. doi:10.1038/nrc2780 CrossRefPubMed

Urakawa I et al (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770–774. doi:10.1038/nature05315 CrossRefPubMed

Usuda J et al (2011a) Klotho predicts good clinical outcome in patients with limited-disease small cell lung cancer who received surgery. Lung Cancer 74:332–337. doi:10.1016/j.lungcan.2011.03.004 CrossRefPubMed

Usuda J et al (2011b) Klotho is a novel biomarker for good survival in resected large cell neuroendocrine carcinoma of the lung. Lung Cancer 72:355–359. doi:10.1016/j.lungcan.2010.10.008 CrossRefPubMed

Wang L et al (2011a) Klotho is silenced through promoter hypermethylation in gastric cancer. Am J Cancer Res 1:111–119PubMedCentralPubMed

Wang X, Chen B, Xu W, Liu S, Zhao W, Wu J (2011b) Combined effects of klotho and soluble CD40 ligand on A549 lung cancer cells. Oncol Rep 25:1465–1472. doi:10.3892/or.2011.1178 PubMed

Wang Y et al (2013) Klotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathway. PLoS One 8:e57391. doi:10.1371/journal.pone.0057391 CrossRefPubMedCentralPubMed

Wolf I et al (2008) Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene 27:7094–7105. doi:10.1038/onc.2008.292 CrossRefPubMed

Wolf I et al (2010) Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin. Oncogene 29:26–33. doi:10.1038/onc.2009.301 CrossRefPubMed

Xie B, Zhou J, Shu G, Liu DC, Chen J, Yuan L (2013a) Restoration of klotho gene expression induces apoptosis and autophagy in gastric cancer cells: tumor suppressive role of klotho in gastric cancer. Cancer Cell Int 13:18. doi:10.1186/1475-2867-13-18 CrossRefPubMedCentralPubMed

Xie B, Zhou J, Yuan L, Ren F, Liu DC, Li Q, Shu G (2013b) Epigenetic silencing of Klotho expression correlates with poor prognosis of human hepatocellular carcinoma. Hum Pathol 44:795–801. doi:10.1016/j.humpath.2012.07.023 CrossRefPubMed

Yakar S, Leroith D, Brodt P (2005) The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev 16:407–420. doi:10.1016/j.cytogfr.2005.01.010 CrossRefPubMed

Yamamoto M et al (2005) Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem 280:38029–38034. doi:10.1074/jbc.M509039200 CrossRefPubMedCentralPubMed

Yamanaka Y et al (1993) Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 53:5289–5296PubMed

Ye X et al (2013) betaKlotho suppresses tumor growth in hepatocellular carcinoma by regulating Akt/GSK-3beta/cyclin D1 signaling pathway. PLoS One 8:e55615. doi:10.1371/journal.pone.0055615 CrossRefPubMedCentralPubMed

Yoon HE et al (2011) Angiotensin II blockade upregulates the expression of Klotho, the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathy. Nephrol Dial Transplant 26:800–813. doi:10.1093/ndt/gfq537 CrossRefPubMedCentralPubMed

Young GH, Wu VC (2012) KLOTHO methylation is linked to uremic toxins and chronic kidney disease. Kidney Int 81:611–612. doi:10.1038/ki.2011.461 CrossRefPubMed

Zhou XX, Wang X (2013) Role of microRNAs in chronic lymphocytic leukemia (Review). Mol Med Rep 8:719–725. doi:10.3892/mmr.2013.1599 PubMed

Zhou L, Li Y, Zhou D, Tan RJ, Liu Y (2013) Loss of Klotho contributes to kidney injury by derepression of Wnt/beta-catenin signaling. J Am Soc Nephrol 24:771–785. doi:10.1681/ASN.2012080865 CrossRefPubMedCentralPubMed

Zhu Y et al (2013) Klotho suppresses tumor progression via inhibiting PI3K/Akt/GSK3beta/Snail signaling in renal cell carcinoma. Cancer Sci 104:663–671. doi:10.1111/cas.12134 CrossRefPubMed

Title: Klotho: a novel biomarker for cancer
Authors: Xiangxiang Zhou
Xin Wang
Publication date: 01-06-2015
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 6/2015
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-014-1788-y

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results and conclusions

Please log in to get access to this content

Other articles of this Issue 6/2015

The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model

Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification

Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer

Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial

Polymorphisms of monocarboxylate transporter genes are associated with clinical outcomes in patients with colorectal cancer

Influence of tumor volume on survival in patients with oral squamous cell carcinoma

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage